Strong sales growth in the middle …

Appearance date: May 06, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Personalis Inc (Nasdaq: PSNL) in the first quarter of 2025 generated sales of over 20 million US dollars with a significant increase in molecular tests.

• The company is well positioned on the growing MRD market and is expected to be grown into a $ 20 billion market.

• Personalis Inc (Nasdaq: PSNL) reported on strong biopharmaceutical sales growth, which is due to the introduction of your next personal test.

• The company has a strong cash position with $ 185.7 million in cash and equivalent and offers a comfortable runway for growth.

• Personalis Inc (NASDAQ: PSNL) makes considerable progress in clinical use and reimbursement efforts with positive feedback from doctors and high retention rates.

• Despite the growth of sales, personalistic inc (Nasdaq: PSNL) a net loss of $ 15.8 million for the first quarter of 2025.

• The company faces challenges with non -reimbursed clinical test costs that affect gross margins.

• The timing and the result of reimbursement decisions consist of uncertainty that could affect future income.

• Personalis Inc (Nasdaq: PSNL) experiences some headwind on the pharmaceutical market due to trade questions and project delays in the pharmaceuticals.

• The company is still in the early stages of data tire and publication for certain cancer ads, which could delay the submission of reimbursement.

Q: Assuming that the reimbursement of breast cancer is going through this year, how will you steer the commercial organization in the direction of breast cancer patients to maximize the reimbursable volume? A: Chris Hall, CEO: We have already focused on breast cancer, lung cancer and therapy monitoring. Our field power aims at doctors who concentrate on these areas. As soon as we have a clear reimbursement, we plan to add more repetitions and to expect the storm to accelerate the efforts.

Q: Can you give insights into the storage of doctors order tests and the growth of new orders? A: Chris Hall, CEO: The retention was high, and several hundred doctors now ordered. The growth is driven by both new and recurring orders, whereby the field force of Tempest contributes significantly. Many new orders include our CGP test, which indicates the preference of doctors for a comprehensive product group.

Q: How do you see today's growth and marketing efforts compared to the subsequent intake? A: Chris Hall, CEO: We are currently measuring growth, but could accelerate by using more repetitions. We exceeded our growth goals and achieved over 50% growth. After the reimbursement, we can switch to higher gears to promote sales growth.